Enliven Therapeutics, Inc. (ELVN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $39.63: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 2.62; Below-average business quality.
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing ELVN-001, a highly selective BCR-ABL tyrosine kinase inhibitor in Phase 1 ENABLE trial for chronic myeloid leukemia (CML), with Phase 3 ENABLE-2 planned for 2H 2026. The company has no approved... Read more
Sell if holding. Engine safety override at $39.63: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 2.62; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.3/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 86d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Enliven Therapeutics, Inc.
Latest news
- Enliven Therapeutics To Present Phase 1 CML Data For ELVN-001, Showing Durable Molecular Response Rates And Favorable Sa — benzinga May 12, 2026 positive
- Goldman Sachs Maintains Buy on Enliven Therapeutics, Raises Price Target to $59 — benzinga May 8, 2026 positive
- Enliven Therapeutics Q1 EPS $(0.38) Beats $(0.46) Estimate — benzinga May 7, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineELVN-00110-K Item 1A: 'We are substantially dependent on ELVN-001. If we are unable to advance ELVN-001 through clinical development, obtain regulatory approval and ultimately commercialize or license ELVN-001...our business will be materially harmed.'
- HIGHSupplierPharmaron10-K Item 1: 'we have obtained the custom-manufactured starting materials for active pharmaceutical ingredients ("APIs") manufacture from Pharmaron and Hande Sciences and our good manufacturing practice ("GMP") APIs from Pharmaron.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $39.63: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 2.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Elevated put/call ratio: 2.62; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $37.62. Score 5.3/10, moderate confidence.
Take-profit target: $49.59 (+25.1% upside). Prior stop was $37.62. Stop-loss: $37.62.
Concentration risk — Pipeline: ELVN-001; Concentration risk — Supplier: Pharmaron; Quality below floor (1.6 < 4.0).
Enliven Therapeutics, Inc. trades at a P/E of N/A (forward -17.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
16 analysts cover ELVN with a consensus score of 4.3/5. Average price target: $57.
What does Enliven Therapeutics, Inc. do?Enliven Therapeutics is a clinical-stage biopharmaceutical company developing ELVN-001, a highly selective BCR-ABL...
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing ELVN-001, a highly selective BCR-ABL tyrosine kinase inhibitor in Phase 1 ENABLE trial for chronic myeloid leukemia (CML), with Phase 3 ENABLE-2 planned for 2H 2026. The company has no approved products or revenue and is substantially dependent on ELVN-001 for all future commercial value.